Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hypofractionated radiation offers 'tailored treatment' approach to RCC mets

Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.

Key clinical point: Hypofractionated radiation therapy (RT) is a safe and efficient treatment strategy in patients with oligometastatic renal cell carcinoma (RCC).

Major finding: In five studies, single-dose RT was used to treat patients with RCC and extracranial metastases; 89% of patients achieved local control, median overall survival (OS) was as high as 21 months, and severe RT-related toxicity occurred 0%-4% of the time.

Study details: A literature review of radiation therapy for RCC.

Disclosures: None.

Read the article

Citation:

Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.